Hepatic Medicine: Evidence and Research (Jul 2024)
Retrospective Database Analysis of Liver-Related Clinical Events in Adult and Pediatric Patients with Alpha-1 Antitrypsin Deficiency in the United States
Abstract
May Hagiwara,1 Victoria Divino,2 Swapna Munnangi,2 Mark Delegge,2 Suna Park,1 Ed G Marins,3 Kaili Ren,4 Charlie Strange5 1Global Evidence and Outcomes, Takeda Development Center Americas, Inc., Cambridge, MA, USA; 2Medical and Scientific Services, IQVIA Inc., Falls Church, VA, USA; 3Global Medical Affairs, Takeda Development Center Americas, Inc., Cambridge, MA, USA; 4Statistics and Quantitative Sciences, Takeda Development Center Americas, Inc., Cambridge, MA, USA; 5Department of Medicine, Medical University of South Carolina, Charleston, SC, USACorrespondence: May Hagiwara, Takeda Development Center Americas, Inc., 500 Kendall Street, Cambridge, MA, 02142, USA, Tel +1 781-482-0426, Email [email protected] and Aims: Real-world analyses on burden of illness in patients with alpha-1 antitrypsin deficiency (AATD) are limited. We investigated the real-world burden of liver-related clinical events among adult and pediatric patients with AATD in the USA.Methods: This was a retrospective, observational analysis of administrative claims data from the IQVIA PharMetrics® Plus and Ambulatory Electronic Medical Records databases from 2011 to 2022. Patients had a diagnosis of liver and/or lung disease with ≥ 180 days of continuous enrollment in the IQVIA PharMetrics Plus database before and ≥ 90 days after their first diagnosis. Follow-up time was assigned to the AATD with liver disease health state or AATD with both liver and lung disease health state (for patients aged ≥ 18 years only). Baseline demographic characteristics and liver-related clinical events of interest were reported.Results: Of 5136 eligible patients, 771 adult and 123 pediatric patients contributed time to the AATD with liver disease health state; 541 adults contributed time to the AATD with both liver and lung disease health state. Among adults, patients with both liver and lung disease had higher rates of liver-related clinical events than patients with liver disease alone. Ascites was the most frequently observed clinical event among adults in both health states, and the median time to the composite of any liver-related clinical event was 26.5 days among all adults combined. Across all pediatric age groups, ascites, gastrointestinal bleed and hepatic encephalopathy were more common than spontaneous bacterial peritonitis and hepatocellular carcinoma, but median time to liver-related clinical event varied by age group at index date and type of event. No liver transplantations occurred in patients aged 6– 17 years.Conclusion: Diagnosed AATD with liver disease carries a substantial burden on adult and pediatric patients; new treatment options are warranted to avoid disease progression to decompensating events.Keywords: alpha-1 antitrypsin deficiency, genetic disease, liver disease, lung disease, pediatric, adult
